AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

About Povorcitinib Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 ...

These games generally receive all the hype and attention, but there are plenty of other initiatives helping the NFL expand around the world, with the International Player Pathway program being a ...

- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del., March 17, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive ...

This inflammatory pathway creates the most scientifically plausible connection between diet and vitiligo progression ... or emerging options like JAK inhibitors when appropriate.

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

In order to support the safe and efficient use of JAK inhibitors in the treatment of patients, an international panel of experts led by MedUni Vienna has published new guidelines. The consensus ...

The conference call will also be webcast live and can be accessed at investor.incyte.com. Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical ...

Evaluate cell proliferation rate through CCK-8; Colony formation experiment to detect cell proliferation; Transwell experiment evaluates cell invasion; Cell scratch assay to detect cell migration; WB ...

Rapid Review Quiz: Advances in Psoriasis Treatment and Management Find out whether you are up to date on the latest advances in psoriasis management with this quick quiz.